MXPA03005393A - Formulacion farmaceutica que contiene pirazolo (4,3-d) pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina. - Google Patents
Formulacion farmaceutica que contiene pirazolo (4,3-d) pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina.Info
- Publication number
- MXPA03005393A MXPA03005393A MXPA03005393A MXPA03005393A MXPA03005393A MX PA03005393 A MXPA03005393 A MX PA03005393A MX PA03005393 A MXPA03005393 A MX PA03005393A MX PA03005393 A MXPA03005393 A MX PA03005393A MX PA03005393 A MXPA03005393 A MX PA03005393A
- Authority
- MX
- Mexico
- Prior art keywords
- prostaglandins
- pyrimidines
- antagonists
- calcium
- pharmaceutical formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10063224A DE10063224A1 (de) | 2000-12-19 | 2000-12-19 | Pharmazeutische Formulierung enthaltend Pyrazolo(4,3-d)pyrimidine und Antithrombotica |
DE2000163882 DE10063882A1 (de) | 2000-12-21 | 2000-12-21 | Pharmazeutische Formulierung enthaltend Pyrazolo[4,3-d]pyrimidine und Calcium-Antagonisten |
DE2000164993 DE10064993A1 (de) | 2000-12-23 | 2000-12-23 | Pharmazeutische Formulierung enthaltend Pyrazolo[4,3-d]pyrimidine und Prostaglandine oder Prostaglandinderivate |
PCT/EP2001/013916 WO2002049651A1 (de) | 2000-12-19 | 2001-11-28 | Pharmazeutische formulierung enthaltend pyrazolo[4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03005393A true MXPA03005393A (es) | 2003-09-25 |
Family
ID=27214208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03005393A MXPA03005393A (es) | 2000-12-19 | 2001-11-28 | Formulacion farmaceutica que contiene pirazolo (4,3-d) pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20040063730A1 (es) |
EP (1) | EP1343506A1 (es) |
JP (1) | JP2004516270A (es) |
KR (1) | KR20030059349A (es) |
CN (1) | CN1481244A (es) |
AR (1) | AR035676A1 (es) |
AU (1) | AU2002229573A1 (es) |
BR (1) | BR0115995A (es) |
CA (1) | CA2431077A1 (es) |
CZ (1) | CZ20031776A3 (es) |
HU (1) | HUP0303315A2 (es) |
MX (1) | MXPA03005393A (es) |
NO (1) | NO20032773L (es) |
PL (1) | PL362513A1 (es) |
SK (1) | SK8192003A3 (es) |
WO (1) | WO2002049651A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR035531A1 (es) * | 2001-01-22 | 2004-06-02 | Novartis Ag | Composicion para el control de plagas endoparasiticas en ganados y animales domesticos, un metodo para su control y el uso de dicha composicion para la preparacion de medicamentos |
ATE478872T1 (de) * | 2002-03-28 | 2010-09-15 | Ustav Ex Botan Av Cr V V I I O | Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung |
DE10229778A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Neue Verwendung von Imidazotriazinonen |
FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
KR100468352B1 (ko) * | 2002-09-24 | 2005-01-27 | 한국과학기술연구원 | 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물 |
EP1620437B1 (en) | 2003-04-29 | 2009-06-17 | Pfizer Limited | 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension |
WO2004110354A2 (en) * | 2003-05-15 | 2004-12-23 | Roskamp Research, Llc | Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
GB0327323D0 (en) * | 2003-11-24 | 2003-12-31 | Pfizer Ltd | Novel pharmaceuticals |
US7572799B2 (en) * | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
DE602005011784D1 (de) * | 2004-04-07 | 2009-01-29 | Pfizer | Pyrazoloä4,3-düpyrimidine |
ES2449340T3 (es) | 2007-03-30 | 2014-03-19 | Amgen Inc. | Compuestos calcimiméticos para su uso en el tratamiento de trastornos intestinales |
CN101883564B (zh) * | 2007-10-05 | 2013-10-16 | 阿尔茨海默病学会美国公司 | 使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法 |
US20100093810A1 (en) * | 2007-10-05 | 2010-04-15 | Alzheimer's Institute Of America, Inc. | Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis |
MX350011B (es) * | 2008-08-13 | 2017-08-22 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas que contienen macitentan. |
US20180015090A1 (en) * | 2015-01-28 | 2018-01-18 | Realinn Life Science Limited | COMPOUNDS FOR ENHANCING PPARy EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF |
CN109923114B (zh) | 2016-09-09 | 2022-11-01 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途 |
AR109595A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
AU2018256459B2 (en) | 2017-04-21 | 2023-12-07 | Ikena Oncology, Inc. | Indole AHR inhibitors and uses thereof |
US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
MX2020008656A (es) | 2018-02-20 | 2020-12-09 | Incyte Corp | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer. |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
JP7399968B2 (ja) | 2018-09-25 | 2023-12-18 | インサイト・コーポレイション | Alk2及び/またはfgfr調節剤としてのピラゾロ[4,3-d]ピリミジン化合物 |
KR20220059480A (ko) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | 고체 형태의 hpk1 억제제 |
EP4065582A1 (en) | 2019-11-26 | 2022-10-05 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2353285A1 (fr) * | 1975-09-17 | 1977-12-30 | Doms Laboratoires | Medicament vasodilatateur coronarien perfectionne |
JPS5459266A (en) * | 1977-10-14 | 1979-05-12 | Ono Pharmaceut Co Ltd | Prostaglandin i2 analogs and their preparation |
FR2568774B2 (fr) * | 1984-05-30 | 1989-05-19 | Choay Sa | Medicaments favorisant les proprietes d'ecoulement du sang et leur utilisation en therapeutique |
FR2672601B1 (fr) * | 1991-02-08 | 1994-10-14 | Synthelabo | Derives de benzo-1,5-thiazepine, leur preparation et leur application en therapeutique. |
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
DE19709877A1 (de) * | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
JP2003525845A (ja) * | 1997-10-28 | 2003-09-02 | ヴィヴァス・インコーポレイテッド | ***機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与 |
DE19942474A1 (de) * | 1999-09-06 | 2001-03-15 | Merck Patent Gmbh | Pyrazolo[4,3-d]pyrimidine |
DE10058662A1 (de) * | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Verwendung von Pyrazolo[4,3-d]pyrimidinen |
DE10103647A1 (de) * | 2001-01-27 | 2002-08-01 | Merck Patent Gmbh | Verfahren zur Herstellung eines Pyrazolo (4,3-d) pyrimidinderivates |
-
2001
- 2001-11-28 CN CNA018209165A patent/CN1481244A/zh active Pending
- 2001-11-28 BR BR0115995-0A patent/BR0115995A/pt not_active Application Discontinuation
- 2001-11-28 CA CA002431077A patent/CA2431077A1/en not_active Abandoned
- 2001-11-28 AU AU2002229573A patent/AU2002229573A1/en not_active Abandoned
- 2001-11-28 SK SK819-2003A patent/SK8192003A3/sk unknown
- 2001-11-28 MX MXPA03005393A patent/MXPA03005393A/es not_active Application Discontinuation
- 2001-11-28 JP JP2002550991A patent/JP2004516270A/ja active Pending
- 2001-11-28 KR KR10-2003-7008078A patent/KR20030059349A/ko not_active Application Discontinuation
- 2001-11-28 WO PCT/EP2001/013916 patent/WO2002049651A1/de not_active Application Discontinuation
- 2001-11-28 PL PL01362513A patent/PL362513A1/xx unknown
- 2001-11-28 US US10/451,105 patent/US20040063730A1/en not_active Abandoned
- 2001-11-28 EP EP01990452A patent/EP1343506A1/de not_active Withdrawn
- 2001-11-28 CZ CZ20031776A patent/CZ20031776A3/cs unknown
- 2001-11-28 HU HU0303315A patent/HUP0303315A2/hu unknown
- 2001-12-19 AR ARP010105888A patent/AR035676A1/es unknown
-
2003
- 2003-06-18 NO NO20032773A patent/NO20032773L/no unknown
Also Published As
Publication number | Publication date |
---|---|
BR0115995A (pt) | 2004-01-13 |
AR035676A1 (es) | 2004-06-23 |
CZ20031776A3 (cs) | 2003-09-17 |
NO20032773D0 (no) | 2003-06-18 |
AU2002229573A1 (en) | 2002-07-01 |
KR20030059349A (ko) | 2003-07-07 |
WO2002049651A1 (de) | 2002-06-27 |
EP1343506A1 (de) | 2003-09-17 |
CN1481244A (zh) | 2004-03-10 |
PL362513A1 (en) | 2004-11-02 |
US20040063730A1 (en) | 2004-04-01 |
HUP0303315A2 (hu) | 2004-01-28 |
NO20032773L (no) | 2003-06-18 |
SK8192003A3 (en) | 2003-10-07 |
CA2431077A1 (en) | 2002-06-27 |
JP2004516270A (ja) | 2004-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03005393A (es) | Formulacion farmaceutica que contiene pirazolo (4,3-d) pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina. | |
AP2002002456A0 (en) | Pyrazolo '4,3-d pyrimidine derivatives | |
HUP0103472A3 (en) | Pyrrolo[2,3-d]pyrimidine derivatives and pharmaceutical compositions containing the same | |
HUP0400692A3 (en) | Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them | |
IL157940A0 (en) | Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient | |
PH31626A (en) | Aqueous risperidone formulations. | |
CA2311483A1 (en) | IMIDAZO [1,2-A] PYRIDINIC ETHERS AND USES THEREOF | |
HRP980398B1 (en) | 5H-THIAZOLO /3,2-a/ PYRIMIDINE DERIVATIVES | |
ZA985121B (en) | 3-Substituted 3,4-dihyrothieno(2,3-d)pyrimidine derivatives their preparation and use. | |
HUP9900607A3 (en) | Pyrido[2,3-d]pyrimidine derivatives and medicinal compositions thereof | |
IL156536A0 (en) | Pyrazolo [3,4-d] pyrimidin-4-one derivatives and pharmaceutical compositions containing the same | |
PL353366A1 (en) | Pyrazolo[4,3-d]pyrimidines | |
HUP0301587A3 (en) | 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect, pharmaceutical compositions containing them and processes for their preparations | |
PL340734A1 (en) | Fungicidal compositions containing derivatives of thiene [2.3-d] pyrimidin-4-one | |
MXPA03004498A (es) | Uso de pirazolo (4,3-d)pirimidinas. | |
ZA987114B (en) | 3-substituted 3,4,5,7-tetrahydropyrrolol[3',4':4,5] thieno[2,3-D]pyrimidine derivatives, their preparation and use. | |
MXPA03006717A (es) | Formulacion farmaceutica que comprende pirazolo (4,3-d) pirimidinas y nitratos o tienopirimidinas y nitratos. | |
MXPA03004907A (es) | Uso de pirazolo (4,3-d) pirimidinas. | |
ZA985120B (en) | 3-Substituted pyrido[3',4':4,5]thieno[2,3-d]pyrimidine derivatives, their preparation and use. | |
ZA200202763B (en) | Pyrazolo [4,3-D] pyrimidine derivatives. | |
SI1210349T1 (en) | PYRAZOLO 4,3-d)PYRIMIDINES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |